THE FACT ABOUT MBL77 THAT NO ONE IS SUGGESTING

mutations specified the fact that, as stated down below, CLL therapy relies within the presence or absence of those mutations. The current consensus is the fact, apart from clonal mutations, subclonal mutations that has a variant allelic frequency ranging from five to 10% (and for that reason below the brink of detection by common molecular methods